Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 87-95 , October 2004

Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy

  • Masakazu Haneda

      Affiliations

    • Second Department of Medicine, Asahikawa Medical College, 1-1-1 Midorigaoka Higashi-Nijyo, Asahikawa, Hokkaido 078-8510, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-166-68-2450; fax: +81-166-68-2459.
    • ,
  • Ryuichi Kikkawa

      Affiliations

    • Shiga University of Medical Science, Otsu, Japan
    • ,
  • Hideto Sakai

      Affiliations

    • Department of Nephrology and Metabolism, School of Medicine, Tokai University, Isehara, Japan
    • ,
  • Ryuzo Kawamori

      Affiliations

    • Department of Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan
    • ,
  • for Candesartan in Diabetic Nephropathy Study Group

Received 11 December 2003 ,Revised 9 February 2004 ,Accepted 20 February 2004.

References 

  1. Statistic Committee of Japan Hemodialysis Society, An overview of dialysis treatment in Japan (as of 31 December 2001), J. Jpn. Soc. Dial. Ther. 36 (2003) 1–31.
  2. UK Prospective Diabetes Study (UKPDS) Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes, Br. Med. J. 317 (1998) 703–713.
  3. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of the HOPE study and MICRO-HOPE substudy, Lancet 355 (2000) 253–259.
  4. Laffel LMB, et al.  The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am. J. Med. 1995;99:497–504
  5. The Microalbuminuria Captopril Study Group, Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria, Diabetologia 39 (1996) 587–593.
  6. Brenner BM, Cooper ME, de Zeeuw D, et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345:861–869
  7. Lewis EJ, Hunsicker LG, Clarke WR, et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345:851–860
  8. Parving HH, Lehnert H, Brochner-Mortensen J, et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001;345:870–878
  9. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Group Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood-pressure-independent effect. Circulation. 2002;106:672–678
  10. Mogensen CE, Neldam S, Tikkanen I, et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. 2000;321:1440–1444
  11. Rossing K, Christensen PK, Hansen BV, Cartensen B, Parving HH. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diab. Care. 2003;26:150–155
  12. Weinberg MS, Weinberg AJ, Cord R, Zappe DH. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS. 2001;2:S196–S198
  13. Apperloo AJ, de Zeeuw D, De Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 1997;51:793–797
  14. Penno G, Chaturvedi N, Talmud PJ, et al.  Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 1998;47:1507–1511
  15. Jacobsen P, Rossing K, Rossing P, et al.  Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 1998;53:1002–1006
  16. Yoshida H, Mitarai T, Kawamura T, et al.  Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J. Clin. Invest. 1995;96:2162–2169
  17. Dudley CR, Keavney B, Stratton IM, Turner RC, Ratcliff PJ. UK Prospective Diabetes Study. XV: relationship of renin-angiotensin system gene polymorphism with microalbuminuria in NIDDM. Kidney Int. 1995;48:1907–1911
  18. Andersen S, Tarnow L, Cambien F, et al.  Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype. Kidney Int. 2002;62:192–198
  19. Andersen S, Tarnow L, Cambien F, et al.  Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype. Diab. Care. 2003;26:1501–1506
  20. Kurokawa K, Abe K, Saruta T, et al.  Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. JRAAS. 2002;3:167–175

PII: S0168-8227(04)00061-0

doi: 10.1016/j.diabres.2004.02.015

Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 87-95 , October 2004

Article Tools

* Image Usage & Resolution